Interpace Biosciences Reports Q2 2022 Financial Results and Improved Diagnostic Accuracy
Interpace Biosciences reported second-quarter revenue of $9.4 million, a 16% decline year-over-year due to a retroactive price cut on its ThyGeNEXT® test by Novitas. The company also noted improved cash collection efficiency with a 15% reduction in Days Sales Outstanding and announced new clinical validation data for its thyroid cancer tests.